Clinical Trial

An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 8, 2024 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study population is comprised of adult males and females with Fabry Disease.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2020-08-17; most recent amendment 2024-04-05.
Status change: Recruiting → Active, Not Recruiting 2023-01-30
Status change: Not Yet Recruiting → Recruiting 2020-09-28
Trial Details
NCT Number NCT04519749
Lead Sponsor 4D Molecular Therapeutics
Conditions Fabry Disease
Enrollment 18 participants
Start Date 2020-09-01
Primary Completion 2026-01 (estimated)
Study Completion 2030-06 (estimated)
Updated on ClinicalTrials.gov 2024-04-08